Geron to Participate at Upcoming Investor Conferences in November
07 Novembre 2023 - 10:30PM
Business Wire
Geron Corporation (Nasdaq: GERN), a late-stage clinical
biopharmaceutical company, today announced that John A. Scarlett,
M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to
present at the following investor conferences:
- Stifel 2023 Healthcare Conference Tuesday, November 14th at
9:10 a.m. ET (Fireside Chat)
- Piper Sandler 35th Annual Healthcare Conference Tuesday,
November 28th at 9:30 a.m. ET (Corporate Presentation)
- 6th Annual Evercore ISI HealthCONx Conference Wednesday,
November 29th at 10:50 a.m. ET (Fireside Chat)
A webcast of each fireside chat and corporate presentation will
be available through the Investor Relations section of the
Company’s website under Events. An archive of the webcast will be
available on the Company’s website for 30 days.
About Geron
Geron is a late-stage clinical biopharmaceutical company
pursuing therapies with the potential to extend and enrich the
lives of patients living with hematologic malignancies. Our
first-in-class investigational telomerase inhibitor, imetelstat,
harnesses Nobel Prize-winning science in a treatment that may alter
the underlying drivers of disease. The New Drug Application (NDA)
for imetelstat for the treatment of transfusion dependent anemia in
adult patients with lower risk myelodysplastic syndromes (LR MDS)
who have failed to respond or have lost response to or are
ineligible for erythropoiesis-stimulating agents (ESAs), based on
the results from the Phase 3 IMerge clinical trial, is currently
under review by the United States Food and Drug Administration
(FDA) with a Prescription Drug User Fee Act (PDUFA) target action
date of June 16, 2024. In addition, an MAA is under review in the
European Union for the same proposed indication. Furthermore, Geron
currently has an ongoing pivotal Phase 3 clinical trial evaluating
imetelstat in relapsed/refractory myelofibrosis (MF). To learn
more, visit www.geron.com or follow us on LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231107595394/en/
Aron Feingold Vice President, Investor Relations and Corporate
Communications
Kristen Kelleher Senior Manager, Investor Relations
investor@geron.com media@geron.com
Grafico Azioni Geron (NASDAQ:GERN)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Geron (NASDAQ:GERN)
Storico
Da Mag 2023 a Mag 2024